PITPNM3

PITPNM3 (Nir1) is a multifunctional membrane-associated protein that serves as a receptor for the chemokine CCL18 and participates in phosphoinositide homeostasis at endoplasmic reticulum–plasma membrane contact sites. As a CCL18 receptor, PITPNM3 activates intracellular calcium signaling, integrin clustering, and multiple downstream pathways including PI3K/Akt/GSK3β/Snail, NF-κB, JAK2/STAT3, and RAC1/ELMO1 to promote cancer cell invasion, epithelial–mesenchymal transition, and metastasis across breast, hepatocellular, lung, and oral cancers (PMID:21481794, PMID:24001613, PMID:26449829, PMID:26756176, PMID:32641093). PITPNM3 constitutively localizes at ER–PM junctions, where it interacts with Nir2 via a region between its FFAT motif and DDHD domain to recruit Nir2 and facilitate PIP2 replenishment during receptor-mediated signaling, and its LNS2 domain binds phosphatidic acid to mediate membrane association (PMID:35020418, PMID:38464273). Missense mutation Q626H in the PYK2-binding domain causes autosomal dominant cone dystrophy (CORD5), and a knock-in mouse model carrying this mutation shows reduced cone electrophysiological responses without structural retinal changes, confirming a role in cone photoreceptor function (PMID:17377520, PMID:41148841).

1. 2007 Medium

   Identification of a disease-causing mutation in PITPNM3 established that this gene is required for normal cone photoreceptor function and linked its PYK2-binding domain to retinal physiology.

   Evidence Genetic mapping and direct sequencing in families with autosomal dominant cone dystrophy (CORD5) identified the Q626H missense mutation

   PMID:17377520

   Open questions at the time

   • Functional interaction with PYK2 inferred from domain mapping rather than demonstrated by direct biochemical assay
   • Mechanism by which Q626H disrupts cone photoreceptor signaling was unknown
   • No animal model at the time to confirm causality
2. 2011 High

   The discovery that PITPNM3 acts as a functional receptor for macrophage-derived CCL18 revealed a previously unknown mechanism by which the tumor microenvironment drives breast cancer invasion and metastasis.

   Evidence Functional receptor identification assay, siRNA knockdown, calcium signaling and integrin clustering assays, and xenograft mouse model in breast cancer cells

   PMID:21481794

   Open questions at the time

   • Structural basis of CCL18–PITPNM3 binding not determined
   • Whether PITPNM3 signals as a classical GPCR or through a distinct mechanism was unclear
   • Relative contribution of PITPNM3 versus other potential CCL18 receptors (e.g., CCR8) was not resolved
3. 2013 Medium

   Mapping the downstream signaling cascade showed that CCL18–PITPNM3 engagement activates PI3K/Akt/GSK3β to stabilize Snail and promote EMT, and phosphorylates LIMK/cofilin to drive actin remodeling, connecting receptor activation to specific pro-metastatic effector pathways.

   Evidence Phosphorylation assays, PI3K inhibitor (LY294002) treatment, siRNA knockdown, and in vivo lung metastasis model in breast cancer

   PMID:24001613

   Open questions at the time

   • Direct physical interaction between PITPNM3 and PI3K not demonstrated
   • Whether PITPNM3's PITP domain contributes to lipid-mediated signaling downstream of CCL18 was not tested
   • Single-lab study without independent replication
4. 2015 Medium

   Extension of CCL18–PITPNM3 signaling to NF-κB activation in hepatocellular carcinoma demonstrated that PITPNM3-mediated pro-invasive signaling operates across multiple cancer types through diverse downstream pathways.

   Evidence siRNA knockdown of PITPNM3, phosphorylation of IKK/IκBα, p65 nuclear translocation, and migration/invasion assays in hepatocellular carcinoma cells

   PMID:26449829

   Open questions at the time

   • Mechanism linking PITPNM3 to IKK phosphorylation not identified
   • Whether NF-κB and Akt/GSK3β pathways are activated simultaneously or context-dependently was unclear
5. 2016 Medium

   Identification of RAC1/ELMO1-dependent cytoskeletal reorganization downstream of CCL18–PITPNM3 in lung cancer cells added a Rho-GTPase signaling axis to the receptor's effector repertoire and linked it to integrin β1-mediated adhesion.

   Evidence RAC1 activation assay, ELMO1 pathway analysis, siRNA knockdown, adhesion and invasion assays in lung cancer cells

   PMID:26756176

   Open questions at the time

   • Direct interaction between PITPNM3 and RAC1 or ELMO1 not shown
   • Relative importance of RAC1/ELMO1 versus Akt and NF-κB axes not compared
6. 2020 Medium

   Two studies expanded the CCL18–PITPNM3 axis: JAK2/STAT3 was identified as another downstream effector in oral cancer, and Mfn-2/SP1-dependent transcriptional suppression of PITPNM3 was identified as an upstream regulatory mechanism in hepatic carcinoma.

   Evidence JAK inhibitor AG490 and siRNA in oral squamous cell carcinoma; Co-IP of Mfn-2/SP1, ChIP on PITPNM3 promoter, and in vivo tumorigenicity assay in hepatic carcinoma

   PMID:31955176 PMID:32641093

   Open questions at the time

   • Whether SP1-dependent transcription is the dominant regulator of PITPNM3 expression across tissues is unknown
   • Both studies from single labs without independent replication
7. 2022 High

   The demonstration that PITPNM3 constitutively resides at ER–PM junctions and recruits Nir2 to maintain PIP2 pools established a receptor-independent lipid-transfer function, revealing a dual role for the protein in both chemokine signaling and phosphoinositide homeostasis.

   Evidence Live-cell imaging, Co-IP with domain mapping (FFAT-DDHD interregion), PIP2 replenishment assays in cultured cells

   PMID:35020418

   Open questions at the time

   • Whether PITPNM3's PITP domain itself transfers lipids was not resolved
   • Relationship between ER-PM junction function and CCL18 receptor activity is unknown
   • Structural basis of Nir1–Nir2 interaction not determined
8. 2022 Medium

   Comparative receptor analysis in microglia demonstrated that CCL18-induced phagocytosis depends on CCR8 rather than PITPNM3, establishing that PITPNM3 is not a universal CCL18 receptor and that cell-type context determines receptor usage.

   Evidence Parallel siRNA knockdown of PITPNM3 and CCR8 with phagocytosis assays and NF-κB/Src pathway analysis in human microglial cells

   PMID:35041514

   Open questions at the time

   • Whether PITPNM3 and CCR8 form heteromeric complexes or compete for CCL18 binding was not tested
   • PITPNM3's role in microglia outside phagocytosis not explored
9. 2025 Medium

   Characterization of the LNS2 domain as a phosphatidic acid sensor provided a molecular mechanism for PITPNM3 membrane targeting and introduced this domain as a potential PA biosensor tool, while a CORD5 knock-in mouse confirmed functional cone impairment in vivo.

   Evidence Liposome binding assays and fluorescent reporters in HEK293A cells (preprint); heterozygous/homozygous knock-in mouse model with ERG and histology

   PMID:38464273 PMID:41148841

   Open questions at the time

   • LNS2/PA binding study is a preprint awaiting peer review
   • Whether PA binding is required for PITPNM3's CCL18 receptor or ER-PM junction functions is untested
   • Mouse CORD5 model shows functional deficit without structural change — mechanism of cone dysfunction remains unresolved

• The structural basis of CCL18 binding to PITPNM3, how PITPNM3's lipid-transfer and chemokine-receptor functions are coordinated, and whether the PITP domain is catalytically active remain major unresolved questions.
• No structure of CCL18–PITPNM3 complex or of full-length PITPNM3
• PITP domain lipid-transfer activity not directly demonstrated
• Relationship between ER-PM junction lipid homeostasis role and chemokine receptor signaling role not addressed